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A standardised, effective systemic therapy for metastatic neuroendocrine tumours (NETs) has not been established to date. We
reviewed the management of 15 patients with inoperable, metastatic NET treated systematically with a combination chemotherapy
regimen of infusional 5-fluorouracil, folinic acid and streptozocin. Overall objective response rate was 53% and tolerability was
excellent.
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Neuroendocrine tumours (NETs) are very rare cancers with
characteristically indolent behaviour. The mainstay of treatment
is surgical resection. However, many tumours metastasise and
cannot be removed, while their behaviour changes to become more
aggressive over time such that the median life expectancy is
approximately 2 years. A range of therapeutic modalities are
available for the treatment of metastatic disease, but none has been
shown convincingly to improve survival in randomised trials.
Treatments offered to patients depend on whether the disease is
hormonally functional and include manipulation with somatosta-
tin analogues, radioisotope therapy and hepatic arterial embolisa-
tion (Caplin et al, 1998). Despite their low growth rate, NETs are
considered to be chemosensitive and responses have been reported
with a range of cytotoxic agents, in particular, streptozocin, 5-
fluorouracil (5FU), doxorubicin, cisplatin and etoposide (Moertel
et al, 1980, 1992; Rivera and Ajani, 1998; Cheng and Saltz, 1999;
Fjallskog et al, 2001).
It has proved difficult to perform high-quality, adequately
powered clinical trials in this rare cancer and few exist in the
literature. In 1980, Eastern Cooperative Oncology Group (ECOG)
published the results of a trial that randomised 84 NET patients to
receive streptozocin chemotherapy or streptozocin combined with
bolus injection of 5FU (Moertel et al, 1980). Combination therapy
achieved a response rate of 63% compared with 36% for single-
agent streptozocin. Streptozocin plus 5FU was subsequently widely
adopted as a standard regimen for treating metastatic NETs. Since
then, only two other chemotherapy regimens have been shown to
rival this level of antitumour activity. The results of another ECOG
trial (Moertel et al, 1992) suggested that doxorubicin was superior
to 5FU when combined with streptozocin, in terms of response rate
(69 vs 45%) and survival (median 2.2 vs 1.4 years). However, a
retrospective analysis of 6 years of treating patients with NETs with
streptozocin plus doxorubicin performed at the Memorial Sloane
Kettering Cancer Center failed to confirm the ECOG trial results,
with only one of 16 patients (6%) treated during that period
achieving an objective radiological response (Cheng and Saltz,
1999). One of the reasons for the discrepancy in response rates
between these two patient groups is that the ECOG trials included a
biochemical response category in addition to conventional
objective tumour reduction in size. Others have done likewise,
and the response rate of 55% achieved by treating 36 patients in
Sweden with cisplatin plus etoposide included nine biochemical
responses (Fjallskog et al, 2001). Using conventional WHO criteria
for measurable disease, the response rate was, in fact, 36%.
All three regimens described here are associated with consider-
able grade III/IV toxicity, in particular, myelosuppression. From
studies primarily in colorectal cancer, it is clear that 5FU
administered as an infusion with or without folinic acid (FA) is
better tolerated and achieves higher response rates compared to
bolus administration. We hypothesised that the standard strepto-
zocin plus bolus 5FU chemotherapy regimen could be improved in
terms of both cytotoxicity and patient tolerance by using an
infusional 5FU regimen well established in colorectal cancer
management (de Gramont et al, 1997). Therefore, we adapted the
standard de Gramont regimen (also known as ‘LV5FU2’ (De
Gramont et al, 1988) to include streptozocin when offering
chemotherapy to patients with metastatic NETs. Here, we review
the results of treating 15 patients with this regimen.
PATIENTS AND METHODS
We analysed retrospectively the treatment of patients with
unresectable NETs, treated in our centre with infusional 5FU, FA
and streptozocin (‘FUFAS’) chemotherapy between January 1997
and December 2002. Histological confirmation of the diagnosis
was obtained in all cases. The chemotherapy regimen comprised a
2-h infusion of FA (200mgm
2), then a bolus injection of 5FU
(400mgm
2), followed by a 22h infusion of 5FU (600mgm
2),
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lcommenced on day 1 and repeated on day 2. Streptozocin
(600mgm
2, maximum dose 1g) was administered on day 2 as
a 30-min infusion. The regimen was repeated every 2 weeks. The
criteria for commencing systemic chemotherapy were: (1) evidence
of rapidly progressive disease on serial CT scan imaging, (2)
extensive hepatic involvement or (3) symptomatic disease in
hormonally functional tumours despite optimal treatment with a
somatostatin analogue. Patients had CT evidence of measurable
disease performed within 4 weeks of commencing treatment and
response was determined independently by consultant members of
the local radiology department, by repeat CT scanning after every
six cycles, using conventional WHO response criteria. The worst
toxicity was recorded for every cycle using NCI Common toxicity
criteria.
RESULTS
A total of 15 patients (eight male, seven female median age 60
years; range 27–68 years) with metastatic, nonpulmonary NETs
were treated. The primary site of the tumour was the pancreas in
six cases, the ovary in one case and unknown in eight patients.
Liver involvement at presentation was evident in 12 (80%) patients.
Four patients had secretory symptoms and had previously been
challenged with a somatostatin analogue. The median number of
cycles of chemotherapy received was six (range 1–14).
One patient achieved a complete response to treatment, seven
patients demonstrated a partial response, two patients had stable
disease and five had progression as best response. Overall objective
response rate was therefore 53%. The median time to progression
was 4 months for all patients and 12 months for responders. Of the
eight responding patients, five had tumours originating in the
pancreas. The overall survival at median follow-up of 27 months
has not yet been reached and eight patients remain alive. No grade
III/IV toxicities occurred. Gastrointestinal toxicities were the most
frequently encountered (WHO Grade II diarrhoea in four
patients). No patient required dose modification or treatment
delays.
DISCUSSION
The ECOG trials combining 5FU bolus injection with streptozocin
indicated a response rate of 63 and 45%, with median survival of
17 months in both cases (Moertel et al, 1980, 1992). Since optimal
administration of 5FU is now considered to be by infusion, we
combined streptozocin with the De Gramont infusional 5FU
regimen, which was well tolerated overall. In our, albeit small
series, efficacy is at least as good as the ECOG data and this
regimen warrants testing further in prospective trials. A UK centre
with a specialist interest in NETs recently reviewed their
experience of administering combination chemotherapy over a
22-year period, when 31 patients were treated (Kaltsas et al, 2002).
However, 23 of these patients received therapeutic modalities in
addition to chemotherapy. Thus, our study is important for being
one of the largest groups of NET patients managed systematically
with a single treatment regimen.
Owing to the low prevalence of NETs, controlled trials are
difficult to perform. Even so, given the wide range of therapeutic
modalities available, many of which have significant costs to both
patients and the health service, evidence is required to better
define their roles in the overall management of this disease. Larger
scale trials are therefore warranted, which would also allow
coordination of tissue collection for research into this tumour,
which is currently poorly understood. For example, genomic and
proteomic studies might serve as prognostic and predictive tools
and assist in therapeutic decisions, as well as providing potential
molecular targets for novel drug development.
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